Enteris BioPharma Inc., a wholly-owned subsidiary of SWK Holdings Corp. (SWKH), is a fully integrated development and manufacturing organization offering innovative oral drug delivery solutions.

Since its founding in 2013, Enteris has adapted its oral drug delivery technology to advance multiple internal and client programs into the clinic. Unlike other technologies, Peptelligence® and ProPerma® uniquely address issues with both solubility and permeability in a solid oral dosage form, enabling new and highly scalable treatment opportunities for compounds that typically need to be injected.

More recently, with the financial support of SWK Holdings Corp., Enteris has completed a renovation of its 32,000 square-foot GMP facility, including HPAPI containment, in Boonton, New Jersey, enabling long-term partnerships for challenging solid oral drug product development from preclinical through commercial cGMP manufacturing.